Practical management of bevacizumab-related toxicities in glioblastoma.

Article Details

Citation
Copy to clipboard

Brandes AA, Bartolotti M, Tosoni A, Poggi R, Franceschi E

Practical management of bevacizumab-related toxicities in glioblastoma.

Oncologist. 2015 Feb;20(2):166-75. doi: 10.1634/theoncologist.2014-0330. Epub 2015 Jan 7.

PubMed ID
25568148 [ View in PubMed
]
Abstract

Bevacizumab, currently an option for treatment of different types of tumors including glioblastoma, has a peculiar toxicity profile related to its antiangiogenic effect. Because some bevacizumab-related adverse events can be life threatening, it is important to identify risk factors and to establish treatment protocols to minimize treatment-related morbidity and mortality. In glioblastoma patients, the risk of developing certain side effects, such as gastrointestinal perforation, venous thromboembolism, and intracranial hemorrhages, is slightly higher than in patients treated with bevacizumab for other tumor types. We performed a systematic review of the side effects of bevacizumab and their incidence, causal mechanisms, and available treatments. Finally, we identified risk factors and proposed preventive and therapeutic measures for these adverse events.

DrugBank Data that Cites this Article

Drugs